Thuy Anh Bui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thuy Anh Bui has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Delvac Oceandy
University of Manchester
3 shared publications - Nicholas Stafford
Michael Smith Building, Dover Street, Manchester, M13 9NT, England
3 shared publications - Elizabeth J. Cartwright
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK
2 shared publications - Meenu Mehta
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India
2 shared publications - Wei Deng
School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia
2 shared publications Abigail Robertson
Division of Cardiovascular Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 4 October 2026
- Published by Wiley in Public Health Challenges
- Vol. 5 (4) , e70396
Post‐COVID‐19 Public Health Challenges: Insights Into Post‐COVID Symptoms, Stigma, and Post‐Pandemic Recovery Support From the Vietnam Experience
Objectives: This study aimed to assess the burden of post‐COVID‐19 symptoms, social stigma, and quality of life, and to examine their interactions among individuals recovering from COVID‐19 in Vietnam. Methods: A cross‐sectional survey was conducted from March to June 2022 among individuals who had recovered from COVID‐19 within 1–3 months prior. Participants completed a self‐administered questionnaire capturing demographic and baseline characteristics, health status during infection, post‐COVID symptoms, perceived social stigma using the five‐item COVID‐19 Perceived Discrimination Scale (C‐19‐PDS), and quality of life using the EQ‐5D‐5L. Multivariable logistic regression was used to investigate the relationship between social stigma and perceived decline in quality of life. Results: Among 764 participants, 55.4% were female, and 45.4% were under 30 years old. Most participants (81.3%) reported at least one of 27 post‐COVID‐19 symptoms, 27.5% experienced social stigma, and 38% reported a decline in quality of life. Perceived social stigma was significantly associated with reduced quality of life (adjusted OR = 1.81; 95% CI 1.20–2.73). Conclusions: Post‐COVID symptoms and social stigma are common among COVID‐19 survivors, and social stigma significantly impacts post‐recovery quality of life. Comprehensive support from families, communities, and authorities is essential to promote full recovery and social integration.
- 4 October 2026
- Published by Wiley in Public Health Challenges
- Vol. 5 (4) , e70396
Open AccessPost‐COVID‐19 Public Health Challenges: Insights Into Post‐COVID Symptoms, Stigma, and Post‐Pandemic Recovery Support From the Vietnam Experience
Objectives: This study aimed to assess the burden of post‐COVID‐19 symptoms, social stigma, and quality of life, and to examine their interactions among individuals recovering from COVID‐19 in Vietnam. Methods: A cross‐sectional survey was conducted from March to June 2022 among individuals who had recovered from COVID‐19 within 1–3 months prior. Participants completed a self‐administered questionnaire capturing demographic and baseline characteristics, health status during infection, post‐COVID symptoms, perceived social stigma using the five‐item COVID‐19 Perceived Discrimination Scale (C‐19‐PDS), and quality of life using the EQ‐5D‐5L. Multivariable logistic regression was used to investigate the relationship between social stigma and perceived decline in quality of life. Results: Among 764 participants, 55.4% were female, and 45.4% were under 30 years old. Most participants (81.3%) reported at least one of 27 post‐COVID‐19 symptoms, 27.5% experienced social stigma, and 38% reported a decline in quality of life. Perceived social stigma was significantly associated with reduced quality of life (adjusted OR = 1.81; 95% CI 1.20–2.73). Conclusions: Post‐COVID symptoms and social stigma are common among COVID‐19 survivors, and social stigma significantly impacts post‐recovery quality of life. Comprehensive support from families, communities, and authorities is essential to promote full recovery and social integration.
- Open Access
- 2 August 2026
- Published by Wiley in Australasian Journal on Ageing
- Vol. 45 (3)
Understanding Patient and Clinician Perspectives in the HITH4Hips Trial: A Qualitative Study
Objectives: Early‐discharge models for hip fracture care are increasingly used to reduce hospital length of stay and healthcare burden, but stakeholder experiences remain underexplored. This study aimed to explore the experiences of patients, carers and healthcare providers (HCPs) involved in a multidisciplinary Hospital In The Home (HITH4Hips) program for low‐trauma hip fractures, and to identify factors influencing its implementation. Methods: Guided by the RE‐AIM QuEST (REach, Adoption, Implementation and Maintenance Qualitative Evaluation for Systematic Translation) framework, semi‐structured interviews were conducted with stakeholders involved in the HITH4Hips program at a metropolitan trauma hospital in Sydney, Australia. Interviews were transcribed verbatim and analysed using a rapid assessment approach with hybrid inductive–deductive coding. Themes were developed through interpretive analysis. Results: Nineteen interviews were completed, including 14 patients/carers (10 HITH4Hips participants; four usual care who declined HITH4Hips, mean age 75 years, 64% women, 86% from culturally and linguistically diverse background) and five HCPs. Four themes were developed: (1) Suitability for HITH: patients preferred home‐based recovery, whereas HCPs were more risk‐averse; (2) Perceptions of program effectiveness: patients prioritised emotional well‐being and functional progress, while HCPs emphasised measurable outcomes; (3) HCP mindset and orientation: role ambiguity and variable staff engagement limited program adoption; and (4) Realising program value: siloed communication and weak inpatient–community linkages hindered implementation. Conclusions: The HITH4Hips program was acceptable and has the potential to reduce healthcare system burden. Successful implementation will require tailored communication strategies and coordinated care pathways to align patient and provider priorities.
- 2 August 2026
- Published by Wiley in Australasian Journal on Ageing
- Vol. 45 (3)
Open AccessUnderstanding Patient and Clinician Perspectives in the HITH4Hips Trial: A Qualitative Study
Objectives: Early‐discharge models for hip fracture care are increasingly used to reduce hospital length of stay and healthcare burden, but stakeholder experiences remain underexplored. This study aimed to explore the experiences of patients, carers and healthcare providers (HCPs) involved in a multidisciplinary Hospital In The Home (HITH4Hips) program for low‐trauma hip fractures, and to identify factors influencing its implementation. Methods: Guided by the RE‐AIM QuEST (REach, Adoption, Implementation and Maintenance Qualitative Evaluation for Systematic Translation) framework, semi‐structured interviews were conducted with stakeholders involved in the HITH4Hips program at a metropolitan trauma hospital in Sydney, Australia. Interviews were transcribed verbatim and analysed using a rapid assessment approach with hybrid inductive–deductive coding. Themes were developed through interpretive analysis. Results: Nineteen interviews were completed, including 14 patients/carers (10 HITH4Hips participants; four usual care who declined HITH4Hips, mean age 75 years, 64% women, 86% from culturally and linguistically diverse background) and five HCPs. Four themes were developed: (1) Suitability for HITH: patients preferred home‐based recovery, whereas HCPs were more risk‐averse; (2) Perceptions of program effectiveness: patients prioritised emotional well‐being and functional progress, while HCPs emphasised measurable outcomes; (3) HCP mindset and orientation: role ambiguity and variable staff engagement limited program adoption; and (4) Realising program value: siloed communication and weak inpatient–community linkages hindered implementation. Conclusions: The HITH4Hips program was acceptable and has the potential to reduce healthcare system burden. Successful implementation will require tailored communication strategies and coordinated care pathways to align patient and provider priorities.
- Top Cited PapersOpen Access
- 1 August 2024
- Published by Elsevier in EBioMedicine
- Vol. 106, 105266
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
- 1 August 2024
- Published by Elsevier in EBioMedicine
- Vol. 106, 105266
Top Cited PapersOpen AccessAdvancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
- Open Access
- 22 June 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 98
Targeted polymer lipid hybrid nanoparticles for in-vitro siRNA therapy in triple-negative breast cancer
- 22 June 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 98
Open AccessTargeted polymer lipid hybrid nanoparticles for in-vitro siRNA therapy in triple-negative breast cancer
- Open Access
Genetic and Pharmacological YAP Activation Induces Proliferation and Improves Survival in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Cardiomyocyte loss following myocardial infarction cannot be addressed with current clinical therapies. Cell therapy with induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) is a potential approach to replace cardiomyocyte loss. However, engraftment rates in pre-clinical studies have been low, highlighting a need to refine current iPSC-CM technology. In this study, we demonstrated that inducing Yes-associated protein (YAP) by genetic and pharmacological approaches resulted in increased iPSC-CM proliferation and reduced apoptosis in response to oxidative stress. Interestingly, iPSC-CM maturation was differently affected by each strategy, with genetic activation of YAP resulting in a more immature cardiomyocyte-like phenotype not witnessed upon pharmacological YAP activation. Overall, we conclude that YAP activation in iPSC-CMs enhances cell survival and proliferative capacity. Therefore, strategies targeting YAP, or its upstream regulator the Hippo signalling pathway, could potentially be used to improve the efficacy of iPSC-CM technology for use as a future regenerative therapy in myocardial infarction.
Open AccessGenetic and Pharmacological YAP Activation Induces Proliferation and Improves Survival in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Cardiomyocyte loss following myocardial infarction cannot be addressed with current clinical therapies. Cell therapy with induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) is a potential approach to replace cardiomyocyte loss. However, engraftment rates in pre-clinical studies have been low, highlighting a need to refine current iPSC-CM technology. In this study, we demonstrated that inducing Yes-associated protein (YAP) by genetic and pharmacological approaches resulted in increased iPSC-CM proliferation and reduced apoptosis in response to oxidative stress. Interestingly, iPSC-CM maturation was differently affected by each strategy, with genetic activation of YAP resulting in a more immature cardiomyocyte-like phenotype not witnessed upon pharmacological YAP activation. Overall, we conclude that YAP activation in iPSC-CMs enhances cell survival and proliferative capacity. Therefore, strategies targeting YAP, or its upstream regulator the Hippo signalling pathway, could potentially be used to improve the efficacy of iPSC-CM technology for use as a future regenerative therapy in myocardial infarction.
- Top Cited PapersOpen Access
- 21 August 2023
- Published by American Chemical Society (ACS) in ACS Materials Au
- Vol. 3 (6) , 600-619
Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development
Over the past decade, the therapeutic potential of nanomaterials as novel drug delivery systems complementing conventional pharmacology has been widely acknowledged. Among these nanomaterials, lipid-based nanoparticles (LNPs) have shown remarkable pharmacological performance and promising therapeutic outcomes, thus gaining substantial interest in preclinical and clinical research. In this review, we introduce the main types of LNPs used in drug formulations such as liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, and lipid polymer hybrid nanoparticles, focusing on their main physicochemical properties and therapeutic potential. We discuss computational studies and modeling techniques to enhance the understanding of how LNPs interact with therapeutic cargo and to predict the potential effectiveness of such interactions in therapeutic applications. We also analyze the benefits and drawbacks of various LNP production techniques such as nanoprecipitation, emulsification, evaporation, thin film hydration, microfluidic-based methods, and an impingement jet mixer. Additionally, we discuss the major challenges associated with industrial development, including stability and sterilization, storage, regulatory compliance, reproducibility, and quality control. Overcoming these challenges and facilitating regulatory compliance represent the key steps toward LNP's successful commercialization and translation into clinical settings.
- 21 August 2023
- Published by American Chemical Society (ACS) in ACS Materials Au
- Vol. 3 (6) , 600-619
Top Cited PapersOpen AccessLipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development
Over the past decade, the therapeutic potential of nanomaterials as novel drug delivery systems complementing conventional pharmacology has been widely acknowledged. Among these nanomaterials, lipid-based nanoparticles (LNPs) have shown remarkable pharmacological performance and promising therapeutic outcomes, thus gaining substantial interest in preclinical and clinical research. In this review, we introduce the main types of LNPs used in drug formulations such as liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, and lipid polymer hybrid nanoparticles, focusing on their main physicochemical properties and therapeutic potential. We discuss computational studies and modeling techniques to enhance the understanding of how LNPs interact with therapeutic cargo and to predict the potential effectiveness of such interactions in therapeutic applications. We also analyze the benefits and drawbacks of various LNP production techniques such as nanoprecipitation, emulsification, evaporation, thin film hydration, microfluidic-based methods, and an impingement jet mixer. Additionally, we discuss the major challenges associated with industrial development, including stability and sterilization, storage, regulatory compliance, reproducibility, and quality control. Overcoming these challenges and facilitating regulatory compliance represent the key steps toward LNP's successful commercialization and translation into clinical settings.
- Open Access
- 22 July 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (20) , 3956-3971
Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU‐MP‐1, protects the heart against adverse effects during pressure overload
Background and Purpose: The Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste‐20 like kinase 1 (Mst1) and mammalian Ste‐20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and fibrosis. Here, we study the effects of pharmacological inhibition of Mst1/2 using a novel inhibitor XMU‐MP‐1 in controlling the adverse effects of pressure overload‐induced hypertrophy.Experimental Approach: We used cultured neonatal rat cardiomyocytes (NRCM) and C57Bl/6 mice with transverse aortic constriction (TAC) as in vitro and in vivo models, respectively, to test the effects of XMU‐MP‐1 treatment. We used luciferase reporter assays, western blots and immunofluorescence assays in vitro, with echocardiography, qRT‐PCR and immunohistochemical methods in vivo.Key Results: XMU‐MP‐1 treatment significantly increased activity of the Hippo pathway effector yes‐associated protein and inhibited phenylephrine‐induced hypertrophy in NRCM. XMU‐MP‐1 improved cardiomyocyte survival and reduced apoptosis following oxidative stress. In vivo, mice 3 weeks after TAC, were treated with XMU‐MP‐1 (1 mg·kg−1) every alternate day for 10 further days. XMU‐MP‐1‐treated mice showed better cardiac contractility than vehicle‐treated mice. Cardiomyocyte cross‐sectional size and expression of the hypertrophic marker, brain natriuretic peptide, were reduced in XMU‐MP‐1‐treated mice. Improved heart function in XMU‐MP‐1‐treated mice with TAC, was accompanied by fewer TUNEL positive cardiomyocytes and lower levels of fibrosis, suggesting inhibition of cardiomyocyte apoptosis and decreased fibrosis.Conclusions and Implications: The Hippo pathway inhibitor, XMU‐MP‐1, reduced cellular hypertrophy and improved survival in cultured cardiomyocytes and, in vivo, preserved cardiac function following pressure overload.
- 22 July 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (20) , 3956-3971
Open AccessPharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU‐MP‐1, protects the heart against adverse effects during pressure overload
Background and Purpose: The Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste‐20 like kinase 1 (Mst1) and mammalian Ste‐20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and fibrosis. Here, we study the effects of pharmacological inhibition of Mst1/2 using a novel inhibitor XMU‐MP‐1 in controlling the adverse effects of pressure overload‐induced hypertrophy.Experimental Approach: We used cultured neonatal rat cardiomyocytes (NRCM) and C57Bl/6 mice with transverse aortic constriction (TAC) as in vitro and in vivo models, respectively, to test the effects of XMU‐MP‐1 treatment. We used luciferase reporter assays, western blots and immunofluorescence assays in vitro, with echocardiography, qRT‐PCR and immunohistochemical methods in vivo.Key Results: XMU‐MP‐1 treatment significantly increased activity of the Hippo pathway effector yes‐associated protein and inhibited phenylephrine‐induced hypertrophy in NRCM. XMU‐MP‐1 improved cardiomyocyte survival and reduced apoptosis following oxidative stress. In vivo, mice 3 weeks after TAC, were treated with XMU‐MP‐1 (1 mg·kg−1) every alternate day for 10 further days. XMU‐MP‐1‐treated mice showed better cardiac contractility than vehicle‐treated mice. Cardiomyocyte cross‐sectional size and expression of the hypertrophic marker, brain natriuretic peptide, were reduced in XMU‐MP‐1‐treated mice. Improved heart function in XMU‐MP‐1‐treated mice with TAC, was accompanied by fewer TUNEL positive cardiomyocytes and lower levels of fibrosis, suggesting inhibition of cardiomyocyte apoptosis and decreased fibrosis.Conclusions and Implications: The Hippo pathway inhibitor, XMU‐MP‐1, reduced cellular hypertrophy and improved survival in cultured cardiomyocytes and, in vivo, preserved cardiac function following pressure overload.
- Open Access
- 2 July 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (22) , 4302-4318
Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials
Mitochondrial dysfunction is considered as a crucial contributory factor in cardiac pathology. This has highlighted the therapeutic potential of targeting mitochondria to prevent or treat cardiac disease. Mitochondrial dysfunction is associated with aberrant electron transport chain activity, reduced ATP production, an abnormal shift in metabolic substrates, ROS overproduction and impaired mitochondrial dynamics. This review will cover the mitochondrial functions and how they are altered in various disease conditions. Furthermore, the mechanisms that lead to mitochondrial defects and the protective mechanisms that prevent mitochondrial damage will be discussed. Finally, potential mitochondrial targets for novel therapeutic intervention will be explored. We will highlight the development of small molecules that target mitochondria from different perspectives and their current progress in clinical trials.Linked Articles: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc
- 2 July 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (22) , 4302-4318
Open AccessMitochondrial function in the heart: the insight into mechanisms and therapeutic potentials
Mitochondrial dysfunction is considered as a crucial contributory factor in cardiac pathology. This has highlighted the therapeutic potential of targeting mitochondria to prevent or treat cardiac disease. Mitochondrial dysfunction is associated with aberrant electron transport chain activity, reduced ATP production, an abnormal shift in metabolic substrates, ROS overproduction and impaired mitochondrial dynamics. This review will cover the mitochondrial functions and how they are altered in various disease conditions. Furthermore, the mechanisms that lead to mitochondrial defects and the protective mechanisms that prevent mitochondrial damage will be discussed. Finally, potential mitochondrial targets for novel therapeutic intervention will be explored. We will highlight the development of small molecules that target mitochondria from different perspectives and their current progress in clinical trials.Linked Articles: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc
- Open Access
- 1 April 2017
- Published by Elsevier in Stem Cell Research
- Vol. 20, 42-49
Genetic ablation of the mammalian sterile-20 like kinase 1 (Mst1) improves cell reprogramming efficiency and increases induced pluripotent stem cell proliferation and survival
- 1 April 2017
- Published by Elsevier in Stem Cell Research
- Vol. 20, 42-49
Open AccessGenetic ablation of the mammalian sterile-20 like kinase 1 (Mst1) improves cell reprogramming efficiency and increases induced pluripotent stem cell proliferation and survival